Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(aminosulfonyl)-N-[(4-fluorophenyl)methyl]-benzamide is a synthetic small molecule belonging to the benzamide class, featuring a sulfonamide group and a para-substituted fluorobenzyl moiety. It is primarily studied as an experimental inhibitor of carbonic anhydrase II, an enzyme involved in the reversible hydration of carbon dioxide. The compound binds with high affinity to carbonic anhydrase II (CA2), acting as a competitive inhibitor at the active site, and has been used in structural biology studies to probe protein-ligand interactions and fluoroaromatic binding effects. There are no approved therapeutic indications or marketed formulations for this compound; it is used mainly in research settings[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(aminosulfonyl)-N-[(4-fluorophenyl)methyl]-benzamide.